Hysterectomy is the standard therapy for placental location trophoblastic tumour. This may be unacceptable to women who want to have children. Cells that have gone awry in a placental site trophoblastic tumour have the capacity to infiltrate normal tissue while avoiding the immune system. The study describes the case of a 23-year-old lady who had a stage I placental location trophoblastic tumour but refused hysterectomy. Tumor test for programmed cell death-ligand 1 staining was done, indicating that the tumour is immune-responsive. The patient began receiving intravenous pembrolizumab 200 mg every two weeks, and by cycle three, her -hCG level was undetectable. She later became pregnant and had an uncomplicated term vaginal birth after a caesarean. She was still free of illness six weeks after giving birth.
Immunotherapy can be used to treat early programmed cell death-ligand 1–positive placental site trophoblastic tumours, resulting in a normal pregnancy.
